374 related articles for article (PubMed ID: 18061455)
21. The use of aromatase inhibitors in adjuvant therapy for early breast cancer.
Jonat W; Hilpert F; Maass N
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():32-8. PubMed ID: 16273366
[TBL] [Abstract][Full Text] [Related]
22. Early recurrence risk: aromatase inhibitors versus tamoxifen.
Bria E; Carlini P; Cuppone F; Vaccaro V; Milella M; Cognetti F
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1239-53. PubMed ID: 20735310
[TBL] [Abstract][Full Text] [Related]
23. Clinical practice decisions in endocrine therapy.
Untch M; Thomssen C
Cancer Invest; 2010; 28 Suppl 1():4-13. PubMed ID: 20653403
[TBL] [Abstract][Full Text] [Related]
24. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
Markopoulos C
Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Wheler J; Johnson M; Seidman A
Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
[TBL] [Abstract][Full Text] [Related]
26. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Ward JH
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
[TBL] [Abstract][Full Text] [Related]
27. The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies.
Pritchard KI; Goss PE; Shepherd L
Breast; 2006 Feb; 15 Suppl 1():S14-20. PubMed ID: 16500236
[TBL] [Abstract][Full Text] [Related]
28. A review of the BIG results: the Breast International Group 1-98 trial analyses.
Doughty JC
Breast; 2008 Jan; 17 Suppl 1():S9-S14. PubMed ID: 18279765
[TBL] [Abstract][Full Text] [Related]
29. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
30. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
Snoj N; Paridaens R; Cufer T
Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
[TBL] [Abstract][Full Text] [Related]
31. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
Goss PE
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():45-52. PubMed ID: 18785006
[TBL] [Abstract][Full Text] [Related]
32. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
33. Prescribing extended adjuvant letrozole.
Gelmon K
Breast; 2007 Oct; 16(5):446-55. PubMed ID: 17544670
[TBL] [Abstract][Full Text] [Related]
34. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
[TBL] [Abstract][Full Text] [Related]
35. [Adjuvant endocrine therapy in breast cancer. Management of early-risk relapse].
Chahine G; Howayek M; Atallah D
J Med Liban; 2009; 57(2):124-9. PubMed ID: 19623889
[TBL] [Abstract][Full Text] [Related]
36. [Current adjuvant endocrine treatment of breast cancer].
Dedes KJ; Gabriel N; Fink D
Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
[TBL] [Abstract][Full Text] [Related]
37. The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98.
Monnier A
Breast; 2006 Feb; 15 Suppl 1():S21-9. PubMed ID: 16500237
[TBL] [Abstract][Full Text] [Related]
38. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Lycette JL; Luoh SW; Beer TM; Deloughery TG
Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
[TBL] [Abstract][Full Text] [Related]
39. Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer.
Tusquets Trías de Bes I; Tormo SS; Mestres JA
Biomed Pharmacother; 2009 Jan; 63(1):1-10. PubMed ID: 18539426
[TBL] [Abstract][Full Text] [Related]
40. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
